Monoclonal antibody specific to full-length free AIM and its applications

JP7874430B2Active Publication Date: 2026-06-16EIKEN KAGAKU +1
View PDF 8 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
EIKEN KAGAKU
Filing Date
2022-03-29
Publication Date
2026-06-16

Smart Images

  • Figure 0007874430000008
    Figure 0007874430000008
  • Figure 0007874430000009
    Figure 0007874430000009
  • Figure 0007874430000010
    Figure 0007874430000010
Patent Text Reader

Abstract

To provide a monoclonal antibody that binds to only a specific form of AIM, and an immunological analysis method for full-length free AIM in a sample using the monoclonal antibody.SOLUTION: The inventors have succeeded in recognizing the SRCR3 domain of AIM, preparing a monoclonal antibody specific to full-length free AIM, and using the monoclonal antibody to immunologically analyze the full-length free AIM in a sample.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Claims

1. A monoclonal antibody that binds to human AIM at positions 263 to 347 and is specific to full-length free AIM.

2. A monoclonal antibody that binds to human AIM at positions 295 to 347 and is specific to full-length free AIM.

3. A method for immunologically analyzing full-length free AIM in a sample, comprising contacting the sample with the monoclonal antibody described in claim 1 or claim 2.

4. A composition for immunologically analyzing full-length free AIM in a sample, comprising the monoclonal antibody described in claim 1 or claim 2.

5. A solid phase for immunologically analyzing full-length free AIM in a sample, to which the monoclonal antibody according to claim 1 or claim 2 is conjugated.

6. A kit for immunological analysis of full-length free AIM in a sample, comprising the composition described in claim 4 or the solid phase described in claim 5.

7. A method for producing a monoclonal antibody that specifically binds to full-length free AIM, comprising the steps of: preparing a monoclonal antibody by immunizing with human AIM or a fragment containing positions 263 to 347; and selecting a monoclonal antibody that binds to positions 263 to 347 of human AIM.

8. A method for producing a monoclonal antibody that specifically binds to full-length free AIM, comprising the steps of: preparing a monoclonal antibody by immunizing with human AIM or a fragment containing positions 295 to 347; and selecting a monoclonal antibody that binds to positions 295 to 347 of human AIM.

9. A therapeutic agent for AIM-related disease comprising the monoclonal antibody according to claim 1 or 2.